Business
Natera Announces New Data at ASCO Highlighting Utility of Personalized MRD Monitoring
Results from the first large, real-world study in 535 gastrointestinal (GI) cancer patients using Signatera™ MRD testing New data using Signatera to monitor
About this update from Natera, Inc.
[{"type":"text","content":"Results from the first large, real-world study in 535 gastrointestinal (GI) cancer patients using Signatera™ MRD testing\n New data using Signatera to monitor treatment response with an immunotherapy-based regimen in hepatocellular carcinoma\n\n\nSAN CARLOS, Calif., May 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, and its collaborators will present new data demonstrating the clinical validity and utility of its personalized molecular residual disease (MRD) assay, Signatera, at the 2020 American Society of Clinical Oncology (ASCO) virtual meeting taking place May 29-31, 2020.\n\n \n \n \n \n \n \n\n \nNatera will present four abstracts — one oral and three poster presentations — showcasing Signatera's ability to track circulating tumor DNA (ctDNA) for residual disease monitoring in colorectal cancer (CRC) and in hepatocellular carcinoma, real-world clinical experience of Signatera MRD assessment in CRC, and the identification and characterization of clonal hematopoiesis of indeterminate potential (CHIP) mutations using Signatera.\n\"We are looking forward to sharing new clinical data at this year's ASCO meeting, which demonstrates our progress towards establishing Signatera as an effective tool for residual disease detection,\" said Alexey Aleshin, M.D., M.B.A., Natera's Senior Medical Director for Oncology. \"The data from these studies support our efforts to set a new standard in residual disease monitoring in patients with colorectal cancer, while expanding ctDNA testing applications to guide optimal treatment options for a broader range of cancer patients.\"\nDetails about the abstracts are as follows:\nAbstract #4009 | Poster discussion #1Presenter: Noelia TarazonaCirculating tumor DNA to detect minimal residual disease, response to adjuvant therapy and to identify patients at high risk of recurrence in patients with stage I-III CRC\nA study evaluating the validity of the Signatera ctDNA assay to detect MRD in CRC patients who are at high risk of recurrence, during and after adjuvant chemotherapy. Serial ctDNA analysis detected MRD up to 16.6 months before radiologic imaging.\nAbstract #3531 | Poster #261Presenter: Chih-Hung HsuLongitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in pati...